Sachin Apte
( out of 25 reviews )

Sachin Apte, MD, MBA, MS

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital North

2K, Gynecology and Mammography
1950 Circle of Hope
Salt Lake City , UT 84112
801-213-4269
Get Directions

Sachin Apte, MD, MS, MBA is Chief Clinical Officer at Huntsman Cancer Institute and Physician-in-Chief of the cancer hospital, part of the University of Utah Health system. Apte is a board-certified gynecologic oncologist and a professor of obstetrics and gynecology at University of Utah Health. He previously served as chair of the department of gynecologic oncology and then as associate chief medical officer at Moffitt Cancer Center.

He is committed to performance excellence by striving for high quality, innovative cancer care delivery that is fully integrated into the research mission, with a focus on value and sustainability for our patients, health system, and the communities we serve. His research program focuses on clinical trials for new investigational therapies in patients with gynecologic cancers, as well as improving surgical quality and outcomes.

He obtained his bachelor of science in chemical engineering from Cornell University and his medical degree from The Ohio State University. He then completed a fellowship in gynecologic oncology at M. D. Anderson Cancer Center while also obtaining his masters of science in cancer biology from the University of Texas Health Science Center at Houston. Apte obtained an MBA from the University of Tennessee in 2012. Apte joined Huntsman Cancer Institute in 2021.

Specialties

Board Certification

American Board of Obstetrics & Gynecology (Obstetrics & Gynecology)
American Board of Obstetrics & Gynecology (Sub: Gynecologic Oncology)

Patient Rating

5.0 /5
( out of 25 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

2025-12-13
HUNTSMAN CANCER CENTER

Dr Apte was the best. I felt valued and validated in every way. He was concerned about my comfort during the exam. He made sure that things were explained throughly in a way I could totally understand. Though surgery is in my near future, I have no doubt that will be carried out with the utmost care and diligence. I'm grateful to have Dr Apte at the helm with my care.

2025-08-16
HUNTSMAN CANCER CENTER

Just excellent. I pray none of my friends or family need his services, but if they do, he's the best.

2025-04-27
HUNTSMAN CANCER CENTER

DR Apte is wonderful. So kind and really cares about you.

2025-04-12
HUNTSMAN CANCER CENTER

DR Apte is very respectful and positive. He does not rush you through through your visit and listen to your concerns.

2025-04-11
HUNTSMAN CANCER CENTER

I am very pleased with the outcome of my surgery that Dr. Apte performed. He made a concerning health issue easy to understand so that I could make an informed decision. He and his staff are kind and caring allowing me to feel welcome and as comfortable as possible. I am happy to recommend him.

2025-01-25
HUNTSMAN CANCER CENTER

Courteous, kind, and just the best!

2024-10-18
HUNTSMAN CANCER CENTER

He so Caring and listens to you. I'm so glad he's Doctor

2024-05-10
HUNTSMAN CANCER CENTER

Very intense knowledge and extremely professional. Both he and his staff are friendly and great communicators.

2024-04-26
HUNTSMAN CANCER CENTER

Very professional

Sachin Apte, MD, MS, MBA is Chief Clinical Officer at Huntsman Cancer Institute and Physician-in-Chief of the cancer hospital, part of the University of Utah Health system. Apte is a board-certified gynecologic oncologist and a professor of obstetrics and gynecology at University of Utah Health. He previously served as chair of the department of gynecologic oncology and then as associate chief medical officer at Moffitt Cancer Center.

He is committed to performance excellence by striving for high quality, innovative cancer care delivery that is fully integrated into the research mission, with a focus on value and sustainability for our patients, health system, and the communities we serve. His research program focuses on clinical trials for new investigational therapies in patients with gynecologic cancers, as well as improving surgical quality and outcomes.

He obtained his bachelor of science in chemical engineering from Cornell University and his medical degree from The Ohio State University. He then completed a fellowship in gynecologic oncology at M. D. Anderson Cancer Center while also obtaining his masters of science in cancer biology from the University of Texas Health Science Center at Houston. Apte obtained an MBA from the University of Tennessee in 2012. Apte joined Huntsman Cancer Institute in 2021.

Board Certification and Academic Information

Academic Departments Obstetrics & Gynecology -Professor
Academic Divisions Gynecological Oncology
Board Certification
American Board of Obstetrics & Gynecology (Obstetrics & Gynecology)
American Board of Obstetrics & Gynecology (Sub: Gynecologic Oncology)

Education history

Undergraduate Chemical Engineering - Cornell University B.S.
Professional Medical Medicine - Ohio State University College of Medicine M.D.
Internship/Residency Obstetrics & Gynecology - Ohio State University College of Medicine Intern/Resident
Graduate Training Cancer Biology - University of Texas, Health Science Center at Houston M.S.
Fellowship Gynecologic Oncology - University of Texas M.D. Anderson Cancer Center Fellow
Graduate Training Business - University of Tennessee M.B.A.

Selected Publications

Journal Article

  1. Hoffman MS, Ondrovic LE, Wenham RM, Apte SM, Shames ML, Zervos EE, Weinberg WS, Roberts WS (2009). Evaluation of the porcine model to teach various ancillary procedures to gynecologic oncology fellows. Am J Obstet Gynecol, 201(1), 116.e1-3.
  2. Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM (2010). Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol, 203(2), 158.e1-40.
  3. Teefey P, Bou Zgheib N, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM (2013). Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. Am J Obstet Gynecol, 208(6), 501.e1-7.
  4. Marchion DC, Xiong Y, Chon HS, Al Sawah E, Bou Zgheib N, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM (2013). Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. Am J Obstet Gynecol, 209(6), 576.e1-576.e16.
  5. Boac BM, Xiong Y, Apte SM, Wenham RM, Shahzad MM, Munroe DG, Lancaster JM, Chon HS (2018). Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer. Am J Obstet Gynecol, 218(4), 436.e1-436.e7.
  6. Hammer DA, Apte SM (1992). Simulation of cell rolling and adhesion on surfaces in shear flow: general results and analysis of selectin-mediated neutrophil adhesion. Biophys J, 63(1), 35-57.
  7. Hammer DA, Tempelman LA, Apte SM (1993). Statistics of cell adhesion under hydrodynamic flow: simulation and experiment. Blood Cells, 19(2), 261-75; discussion 275-7.
  8. Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM (2012). In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer, 106(12), 1967-75.
  9. Vaccarello L, Apte SM, Diaz PT, Lewandowski GS, Copeland L (1997). Respiratory failure from metastatic choriocarcinoma: a survivor of mechanical ventilation. Gynecologic oncology, 67(1), 111-4.
  10. Vaccarello L, Apte SM, Copeland LJ, Boutselis JG, Rubin S (1999). Endometrial carcinoma associated with pregnancy: A report of three cases and review of the literature. Gynecologic oncology, 74(1), 118-22.
  11. Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler I (2004). Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecologic oncology, 93(1), 78-86.
  12. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman R (2009). A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecologic oncology, 113(2), 210-5.
  13. Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Bou Zgheib N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster J (2012). The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecologic oncology, 124(1), 119-24.
  14. Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord A (2013). A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecologic oncology, 130(1), 19-24.
  15. Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Bou Zgheib N, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster J (2013). Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. Gynecologic oncology, 131(1), 207-12.
  16. Boac BM, Xiong Y, Marchion DC, Abbasi F, Bush SH, Ramirez IJ, Khulpateea BR, Clair McClung E, Berry AL, Bou Zgheib N, Chon HS, Shahzad MM, Judson PL, Wenham RM, Apte SM, Berglund AE, Magliocco AM, Lancaster J (2016). Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance. Gynecologic oncology, 140(2), 259-63.
  17. Liang MI, Aviki EM, Wright JD, Havrilesky LJ, Boyd LR, Moss HA, Jewell EL, Cohn DE, Apte SM, Timmins PF 3rd, Alvarez RD, Rathbun J, Lipinski E, White S, Siverio-Minardi D, Ko E (2020). Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models. Gynecologic oncology, 156(3), 701-709.
  18. Rishi A, Rollins M, Ahmed KA, Hunt DC, Sarkar P, Fernandez DC, Hoffman MS, Apte SM, Shahzad MMK, Chon HS, Chern JY, Wenham RM, Montejo M (2020). High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity. Gynecologic oncology, 156(2), 349-356.
  19. Hoffman MS, Xiong Y, Apte S, Roberts W, Wenham R (2019). Twenty-year surgical trends in a gynecologic oncology fellowship training program: Implications for practice. Gynecologic oncology, 155(2), 359-364.
  20. Bulls HW, Hoogland AI, Kennedy B, James BW, Arboleda BL, Apte S, Chon HS, Small BJ, Gonzalez BD, Jim HS (2019). A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Gynecologic oncology, 152(2), 310-315.
  21. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster J (2009). MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecologic oncology, 113(2), 249-55.
  22. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen DT, Dressman H, Lancaster J (2008). MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecologic oncology, 110(2), 206-15.
  23. Bumgardner GL, Li J, Apte S, Heininger M, Frankel W (1998). Effect of tumor necrosis factor alpha and intercellular adhesion molecule-1 expression on immunogenicity of murine liver cells in mice. Hepatology (Baltimore, Md.), 28(2), 466-74.
  24. Phillips KM, Faul LA, Small BJ, Jacobsen PB, Apte SM, Jim H (2013). Comparing the retrospective reports of fatigue using the Fatigue Symptom Index with daily diary ratings in women receiving chemotherapy for gynecologic cancer. Journal of pain and symptom management, 46(2), 282-8.
  25. Bansal N, Roberts WS, Apte SM, Lancaster JM, Wenham R (2009). Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations. Journal of surgical oncology, 100(6), 511-4.
  26. Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster J (2011). BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clinical cancer research, 17(19), 6356-66.
  27. Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, Fidler I (2002). Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clinical cancer research, 8(7), 2413-22.
  28. Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster J (2013). A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncology reports, 29(5), 2011-8.
  29. Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, Cheng JQ, Sellers TA, Lancaster J (2014). Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncology reports, 31(1), 376-83.
  30. Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster J (2012). The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. International journal of oncology, 41(1), 179-88.
  31. Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Bou Zgheib N, Boac BM, Orr BC, Judson PL, Berry A, Hakam A, Wenham RM, Apte SM, Berglund AE, Lancaster J (2015). BAD-mediated apoptotic pathway is associated with human cancer development. International journal of molecular medicine, 35(4), 1081-7.
  32. Jim HS, Small B, Faul LA, Franzen J, Apte S, Jacobsen P (2011). Fatigue, depression, sleep, and activity during chemotherapy: daily and intraday variation and relationships among symptom changes. Annals of behavioral medicine, 42(3), 321-33.
  33. Apte S (2017). An oncologist's perspective: preparation for new payment models in cancer care. The American journal of managed care, 23(5 Spec No.), SP169-SP172.
  34. Humphrey MM, Apte S (2009). The use of minimally invasive surgery for endometrial cancer. Cancer control, 16(1), 30-7.
  35. Ramirez I, Chon HS, Apte S (2011). The role of surgery in the management of epithelial ovarian cancer. Cancer control, 18(1), 22-30.
  36. Bush SH, Apte S (2015). Robotic-Assisted Surgery in Gynecological Oncology. Cancer control, 22(3), 307-13.
  37. Chon HS, Kang S, Lee JK, Apte SM, Shahzad MM, Williams-Elson I, Wenham R (2017). Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. BMC cancer, 17(1), 407.
  38. Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Bou Zgheib N, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster J (2012). Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. International journal of gynecological cancer, 22(6), 960-7.
  39. Abdallah R, Bush SH, Chon HS, Apte SM, Wenham RM, Shahzad M (2016). Therapeutic Dilemma: Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix. International journal of gynecological cancer, 26(3), 553-60.
  40. Kuznicki M, Mallen A, McClung EC, Robertson SE, Todd S, Boulware D, Martin S, Quilitz R, Vargas RJ, Apte S (2020). Dual antibiotic prevention bundle is associated with decreased surgical site infections. International journal of gynecological cancer, 30(9), 1411-1417.
  41. Kamath SG, Chen N, Xiong Y, Wenham R, Apte S, Humphrey M, Cragun J, Lancaster J (2009). Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. International journal of gynecological cancer, 19(9), 1564-9.
  42. Apte SM, Vadhan-Raj S, Cohen L, Bassett RL, Gordon IO, Levenback CF, Ramirez PT, Gallardo ST, Patenia RS, Garcia ME, Iyer RB, Freedman R (2006). Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. Journal of translational medicine, 4, 16.
  43. Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR 3rd, Martin L, Morgan MA, Morgan RJ Jr, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Valea FA, National Comprehensive Cancer Networks (2010). Cervical cancer. Journal of the National Comprehensive Cancer Network, 8(12), 1388-416.
  44. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL 2nd, Han E, Huh WK, Lurain JR 3rd, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M, National Comprehensive Cancer Network (2013). Cervical cancer. Journal of the National Comprehensive Cancer Network, 11(3), 320-43.
  45. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Fader AN, Fisher CM, Gaffney DK, George S, Han E, Huh WK, Lurain JR 3rd, Martin L, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FA, McMillian N, Hughes (2014). Uterine neoplasms, version 1.2014. Journal of the National Comprehensive Cancer Network, 12(2), 248-80.
  46. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR 3rd, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Teng N, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone J (2015). Cervical Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network, 13(4), 395-404.
  47. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR 3rd, Mariani A, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL, National Comprehensive Cancer Network (2015). Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network, 13(11), 1321-31.
  48. Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster J (2012). BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. Journal of gynecologic oncology, 23(1), 35-42.
  49. Bou Zgheib N, Marchion DC, Bush SH, Judson PL, Wenham RM, Apte SM, Lancaster JM, Gonzalez-Bosquet (2016). Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer. Oncology letters, 11(1), 323-329.
  50. Mark J, Bush S, Glazer E, Strosberg J, Saglam O, Apte S (2015). Metastatic VIPoma presenting as an ovarian mass. International journal of surgery case reports, 17, 167-9.
  51. Bush SH, Tollin S, Marchion DC, Xiong Y, Abbasi F, Ramirez IJ, Zgheib NB, Boac B, Judson PL, Chon HS, Wenham RM, Apte SM, Cubitt CL, Berglund AE, Havrilesky LJ, Lancaster J (2016). Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. Molecular and clinical oncology, 4(3), 399-404.
  52. Wenham RM, Buras AL, Gordon SW, Whiting J, Fridley BL, Dorman D, Apte SM, Chon HS, Shahzad MM, Randall LM, Havrilesky LJ, Davidson BA, Secord A (2025). A Phase 2 Study of Pembrolizumab and Weekly Paclitaxel for Platinum-Resistant Epithelial Ovarian Cancer. International Journal of Gynecological Cancer,

Case Report

  1. Wells AE, Mallen AM, Bui MM, Reed DR, Apte S (2019). NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report. Gynecologic oncology reports, 28, 141-144.

News & Podcasts

Huntsman Cancer Institute News